enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
enGene Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire • 03/09/26
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Business Wire • 02/04/26
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.Business Wire • 01/20/26
enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing ReadinessBusiness Wire • 12/02/25
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness Wire • 11/13/25
enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC TranscriptSeeking Alpha • 11/11/25
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND TrialBusiness Wire • 11/10/25
enGene Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 09/11/25
EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
enGene Announces Board and Leadership Appointments to Support Commercial ReadinessBusiness Wire • 07/08/25
FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder CancerBusiness Wire • 06/25/25
enGene Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 06/12/25